Mebias Discovery holds a game-changing platform to discover next generation GPCR drugs devoid of on-target side effects once thought to be unavoidable.

We partner with investors to discover and progress pathway selective GPCR drugs.


Fully validated assay suite correlating ligand-induced dynamic conformation of GPCR to pathway-specific signaling.


Differentiated mu-opioid receptor drug candidates for the treatment of pain.


Seeking additional investors to collaborate and co-develop GPCR drugs without receptor associated side effects.